-
Mashup Score: 2Uptake of Aspirin as Lynch Syndrome Chemoprevention Remains Low. What Oncologists Need to Know to Support Patients - 2 day(s) ago
Only about one-third of patients with Lynch syndrome are using aspirin or nonsteroidal anti-inflammatory agents as a form of chemoprevention, according to a new study published in JCO Precision Oncology.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 9Adoptive Cell Therapy in Solid Tumors: How Can We Mitigate Risk and Optimize Rewards? - 3 day(s) ago
Although immune checkpoint inhibitor therapy has revolutionized the treatment of solid tumors, immunologically “cold” tumors remain difficult to treat. Adoptive cell therapy—particularly, tumor-infiltrating lymphocyte therapy—shows promise in this space.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
When it comes to adoptive cell therapy for solid tumors, how can we mitigate the risks and optimize the rewards? @BiachiTiago of @MoffittNews explores the various challenges around ACT in a new editorial for #ASCODailyNews: https://t.co/KoiBDM9vNq https://t.co/RQGB2vSMj7
-
-
Mashup Score: 1Adoptive Cell Therapy in Solid Tumors: How Can We Mitigate Risk and Optimize Rewards? - 3 day(s) ago
Although immune checkpoint inhibitor therapy has revolutionized the treatment of solid tumors, immunologically “cold” tumors remain difficult to treat. Adoptive cell therapy—particularly, tumor-infiltrating lymphocyte therapy—shows promise in this space.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
When it comes to adoptive cell therapy for solid tumors, how can we mitigate the risks and optimize the rewards? @BiachiTiago of @MoffittNews explores the various challenges around ACT in a new editorial for #ASCODailyNews: https://t.co/KoiBDM9vNq https://t.co/RQGB2vSMj7
-
-
Mashup Score: 32
Two-thirds of patients with advanced cancer whose biopsies were tested using an in-house comprehensive genomic profiling assay were found to be candidates for precision therapies, according to a study at a large U.S. health system. The study also found a survival advantage among patients who received targeted therapies versus those who received chemotherapy alone.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival https://t.co/AjCFIQQ2bC @asco
-
-
Mashup Score: 28
Two-thirds of patients with advanced cancer whose biopsies were tested using an in-house comprehensive genomic profiling assay were found to be candidates for precision therapies, according to a study at a large U.S. health system. The study also found a survival advantage among patients who received targeted therapies versus those who received chemotherapy alone.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival https://t.co/AjCFIQQ2bC @asco
-
-
Mashup Score: 26
Two-thirds of patients with advanced cancer whose biopsies were tested using an in-house comprehensive genomic profiling assay were found to be candidates for precision therapies, according to a study at a large U.S. health system. The study also found a survival advantage among patients who received targeted therapies versus those who received chemotherapy alone.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival https://t.co/AjCFIQQ2bC @asco
-
-
Mashup Score: 26
Two-thirds of patients with advanced cancer whose biopsies were tested using an in-house comprehensive genomic profiling assay were found to be candidates for precision therapies, according to a study at a large U.S. health system. The study also found a survival advantage among patients who received targeted therapies versus those who received chemotherapy alone.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival https://t.co/AjCFIQQ2bC @asco
-
-
Mashup Score: 3
Three recent updates may alter the TKI selection paradigm in chronic myeloid leukemia chronic phase: asciminib has shown high response rates and few adverse events, generic imatinib has decreased in cost significantly, and dasatinib is now a generic drug. While imatinib and dasatinib are attractive and effective frontline options, asciminib’s high cost may render it more appropriate for patients who experience tolerability issues with other TKIs.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
What's the best frontline TKI for newly diagnosed CML-CP? Recent updates re: effectiveness and cost may alter the selection paradigm. @KellySchoenbeck, @MazieTsangMD & Dr. Neil P. Shah explore the options for #ASCODailyNews: https://t.co/LrkqRjXPzh #ChronicMyeloidLeukemia #leusm https://t.co/ICFpAmQnZB
-
-
Mashup Score: 0
The role of ctDNA in disease detection and treatment selection continues to grow in importance and scope in both the metastatic and early breast cancer settings.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
ctDNA has assumed an important role in disease detection and treatment selection for metastatic and early breast cancers, and researchers are exploring how to increase its utility even further. #ASCODailyNews has more: https://t.co/iPKzpf5Qrz
-
-
Mashup Score: 5Pursuing Moving Targets: Assessing Target Expression to Maximize ADC Efficacy in Patients With Metastatic Breast Cancer - 12 day(s) ago
ADCs offer therapeutic promise for patients with metastatic breast cancer, with a key factor of their effectiveness being the expression of specific target antigens.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Though ADCs have emerged as a cutting-edge approach to #chemotherapy, determining when & how to assess targets in pts w/ metastatic #BreastCancer remains an evolving challenge. @YAbdouMD & @paolazagam discuss in a new editorial for #ASCODailyNews: https://t.co/3SjQWFXtfc #bcsm https://t.co/Ksnb2Ndbzq
-
Only about 1/3 of patients w/ #LynchSyndrome are using aspirin/NSAIDs as a form of chemoprevention, according to a recent study published in @JCOPO_ASCO. #ASCODailyNews covers the study & discusses what oncologists need to know to support patients: https://t.co/Y9ajkWt9UF https://t.co/mwz6cpUYpf